These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7763199)

  • 1. Lack of a fast-acting effect of erythropoietin on arterial blood pressure and endothelin level.
    Hon G; Vaziri ND; Kaupke CJ; Tehranzadeh A; Barton C
    Artif Organs; 1995 Feb; 19(2):188-91. PubMed ID: 7763199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin.
    Takahashi K; Totsune K; Imai Y; Sone M; Nozuki M; Murakami O; Sekino H; Mouri T
    Clin Sci (Lond); 1993 Jan; 84(1):47-50. PubMed ID: 8382133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin-mediated effect of erythropoietin on blood pressure and renal hemodynamics in hypertensive rats.
    Tojo A; Doumoto M; Oka K; Numabe A; Kimura K; Yagi S
    Am J Physiol; 1996 Apr; 270(4 Pt 2):R744-8. PubMed ID: 8967402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin-induced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or atrial natriuretic peptide levels.
    Zhou XJ; Pandian D; Wang XQ; Vaziri ND
    J Am Soc Nephrol; 1997 Jun; 8(6):901-5. PubMed ID: 9189856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acute effects of human recombinant erythropoietin on cardiovascular dynamics and vasoactive substances].
    Suga M; Kurihara S; Iino Y; Terashi A
    Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):634-9. PubMed ID: 9014484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
    Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients.
    Kang DH; Yoon KI; Han DS
    Nephrol Dial Transplant; 1998 Nov; 13(11):2877-83. PubMed ID: 9829494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
    Jungers P; Choukroun G; Oualim Z; Robino C; Nguyen AT; Man NK
    Nephrol Dial Transplant; 2001 Feb; 16(2):307-12. PubMed ID: 11158405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.
    Kuriyama S; Tomonari H; Yoshida H; Hashimoto T; Kawaguchi Y; Sakai O
    Nephron; 1997; 77(2):176-85. PubMed ID: 9346384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
    Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
    Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects.
    Thomsen LL; Iversen HK; Emmeluth C; Bie P
    Eur J Clin Pharmacol; 1995; 48(2):139-42. PubMed ID: 7589028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease.
    Dhaun N; Macintyre IM; Melville V; Lilitkarntakul P; Johnston NR; Goddard J; Webb DJ
    Hypertension; 2009 Jul; 54(1):113-9. PubMed ID: 19506099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease.
    Dhaun N; MacIntyre IM; Kerr D; Melville V; Johnston NR; Haughie S; Goddard J; Webb DJ
    Hypertension; 2011 Apr; 57(4):772-9. PubMed ID: 21357275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin.
    Jensen JD; Madsen JK; Jensen LW
    Eur J Clin Pharmacol; 1996; 50(3):171-7. PubMed ID: 8737755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of recombinant human erythropoietin in predialysis patients.
    Portolés J; Torralbo A; Martin P; Rodrigo J; Herrero JA; Barrientos A
    Am J Kidney Dis; 1997 Apr; 29(4):541-8. PubMed ID: 9100042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin: 18 months' experience in hemodialysis patients.
    Canaud B; Polito-Bouloux C; Garred LJ; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Am J Kidney Dis; 1990 Feb; 15(2):169-75. PubMed ID: 2301388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of blood pressure in end-stage renal disease with platelet cytosolic free calcium concentration during treatment of renal anemia with recombinant human erythropoietin.
    Schiffl H
    Int J Artif Organs; 1992 Jun; 15(6):343-8. PubMed ID: 1639525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.
    Goddard J; Johnston NR; Hand MF; Cumming AD; Rabelink TJ; Rankin AJ; Webb DJ
    Circulation; 2004 Mar; 109(9):1186-93. PubMed ID: 14981006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.